Novel Imaging and Biofluid Biomarkers of Small Vessel Cerebrovascular Disease

项目总结/摘要 小血管脑血管疾病在老年人中很常见，并且是众所周知的认知能力下降的原因。然而，该领域的一个主要差距是持续需要适用于早期检测、疾病监测和测量治疗效果的可靠且可重复的血管疾病生物标志物。该提案的总体目标是临床验证NIND选择的脑血管疾病的新型神经影像学和基于液体的生物标志物，这些生物标志物是在MarkVCID联盟的前五年开发的。我们建议纵向跟踪200名不同的老年受试者队列，这些受试者存在一系列脑血管负担、认知主诉和功能下降。我们的目标是验证MarkVCID生物标志物，并解决这些生物标志物和阿尔茨海默病病理生理学之间可能的相互作用。实现这些目标将改善老年受试者小血管脑血管病的早期检测、诊断和预后，并为临床试验提供更好的目标和结局指标。

PROJECT SUMMARY/ABSTRACT Small vessel cerebrovascular disease is common in the elderly and is a well-known contributor to cognitive decline. A major gap in the field, however, is the ongoing need for reliable and reproducible biologic markers of vascular disease suitable for early detection, disease monitoring, and measuring treatment efficacy. The overarching goal of this proposal is to clinically validate novel neuroimaging and fluid-based biomarkers of a cerebrovascular disease selected by the NINDs and developed during the first five years of the MarkVCID consortium. We propose to longitudinally follow a cohort of 200 diverse, older subjects who present with a range of cerebrovascular burdens and cognitive complaints, and functional decline. Our aims are to validate the MarkVCID biomarkers and address possible interactions between these biomarkers and Alzheimer’s disease pathophysiology. Accomplishing these goals will improve the early detection, diagnosis, and prognosis of small vessel cerebrovascular disease in older subjects and provide better targets and outcome metrics for clinical trials.